A diet rich in fruits, vegetables and low-fat dairy products, and reduced in saturated fat, total fat and cholesterol (the 'DASH' diet) significantly lowers blood pressure (BP). Previous studies have documented that certain therapies that lower BP increase plasma renin activity (PRA). Using data from the Dietary Approaches to Stop Hypertension (DASH) trial, we assessed the effects of dietary patterns on PRA and determined the relationship of change in PRA with change in BP on each diet. After eating a control diet for 3 weeks, participants were then randomized to receive for 8 weeks: the control diet, a diet rich in fruits and vegetables (F/V), or the DASH diet. Baseline and follow-up levels of PRA were available in 381 participants. Compared with the control diet, the DASH diet increased PRA by 0.37 ng ml À1 h À1 (P ¼ 0.01). In multivariable linear regression analyses, there was an inverse association of PRA change with systolic BP change on the control diet (slope ¼ À0.35, P ¼ 0.001), but PRA did not differ by BP change on the F/V diet (slope ¼ À0.002, P ¼ 0.98) or DASH diet (slope ¼ À0.08, P ¼ 0.32). These data suggest that a blunted counter-regulatory response of the reninangiotensin system is associated with the BP-lowering effect of the F/V and DASH diets.
Introduction
The renin-angiotensin system has an important role in blood pressure (BP) homeostasis. 1 When BP falls or when intravascular volume is reduced, the kidneys secrete renin, a counter-regulatory hormone that tends to increase BP and intravascular volume by decreasing sodium excretion.
2 Several BP-lowering therapies, such as sodium reduction and diuretics, activate the renin-angiotensin system and raise plasma renin activity (PRA). [3] [4] [5] The Dietary Approaches to Stop Hypertension (DASH) trial documented that the DASH diet (a diet rich in fruits, vegetables and low-fat dairy products, and reduced in saturated fat, total fat and cholesterol) lowers BP substantially. 6, 7 The mechanisms responsible for the BP-lowering effects of this diet are uncertain.
The objectives of this paper are to document and compare the effects of three dietary patterns on PRA and to determine the relationship of change in PRA with change in BP.
Methods
Detailed information about the DASH study design has been published previously. 7, 8 The DASH trial was a randomized, multi-center, controlled feeding study. The study centers provided participants all of their food for 11 weeks. Institutional review boards approved the study protocol. Written informed consent was obtained from all participants.
Study population
The DASH trial enrolled 459 adults, 22 years of age or older, who were not taking any anti-hypertensive medications. Each participant had an average screening systolic BP (SBP) of o160 mm Hg and average screening diastolic BP of 80-95 mm Hg. Major exclusion criteria were diabetes mellitus, hyperlipidemia, a cardiovascular event within the previous 6 months, pregnancy or lactation, body-mass index 435 kg m
À2
, use of anti-hypertensive medication, renal insufficiency or high alcohol intake. Participants were enrolled sequentially from September 1994 to January 1996.
Trial design
The trial was conducted in three phases (screening, run-in and intervention). After the screening phase, interested and eligible persons started a 3-week run-in period, during which all individuals were provided the control diet, described below. The intervention phase was an 8-week period in which individuals were provided their randomly assigned diet. The three randomized diets were a control diet, a 'fruits and vegetables' (F/V) diet, and the 'DASH' diet. The control diet was typical of what many Americans eat and was relatively low in potassium, magnesium and calcium, and high in saturated fat, total fat and cholesterol. The F/V diet was rich in potassium, magnesium and fiber, but otherwise similar to the control diet. The DASH diet was rich in potassium, magnesium, calcium, fiber and protein, and reduced in saturated fat, total fat and cholesterol. Sodium content was similar in all diets. During the run-in and intervention periods, the weight of each participant was held constant. 8 
Measurements
At each visit, BP was measured in duplicate by trained, certified staff using a random-zero sphygmomanometer and by following a standard protocol. Baseline BP was defined as the average of the sets of measurements taken on 3 days during the screening phase and on 4 days during run-in. End-of-intervention BP was defined as the average of the five sets of measurements obtained on separate days during the last 2 weeks of the intervention period. BP change was defined as the difference between the end-of-intervention and baseline BP.
PRA was measured twice, once during the last week of the run-in period and another during the last week of the intervention period. A venous blood sample for PRA was collected after each participant had an overnight fast and had been upright for at least 90 min. The samples were stored at À70 1C. PRA was measured by radioimmunoassay at a central laboratory. The stored samples were incubated at 37 1C for 30 or 60 min. PRA was calculated as the difference between the angiotensin I-like activity in unincubated plasma and that generated during incubation. 9 Because of the right-skewed distribution of PRA, we report natural log PRA (log e PRA) for baseline PRA as well as absolute PRA level. Change in PRA is expressed both as absolute change in PRA and the change in log e PRA (Dlog e-PRA). Absolute change was the difference between end-of-intervention and baseline PRA values.
A 24-h urine sample was collected during the last week of run-in and during the last week of the intervention period, and sent to a central laboratory for analyses of sodium and potassium.
Statistical analyses
Data were analyzed using Stata statistical software (Release 9.0, Stata Corporation, College Station, TX, USA, 2005). Baseline PRA levels were reported as median (Q1, Q3). Other continuous variables were reported as mean±s.d. For the trial outcomes of BP and absolute levels of PRA, between-diet comparisons were made using analyses of variance. To assess the relationship between PRA change and BP change in each diet groups, we performed multivariate linear regression analyses stratified by diet. In these analyses, the dependent variable was the Dlog e PRA, the independent variable was change in SBP (DSBP), and adjustment variables were baseline SBP, age, sex, race and baseline log e PRA. Change in diastolic BP was not significantly correlated with Dlog e PRA, and thus was not included in the linear regression model. Multicollinearity was assessed using the variance inflation factor. None of the variance inflation factor values were above 4.5, suggesting that collinearity was not likely to be a concern. To determine if the relationship between change in PRA and change in BP was similar in the three diets, we performed analyses of covariance. In these analyses, we calculated pairwise between-diet differences in the slope of Dlog e PRA with DSBP. A P-value o0.05 (two-sided) was considered statistically significant.
Results
Among 459 randomized participants, PRA levels at both baseline and end of intervention were available for 381 (83%) participants. Baseline characteristics of these 381 participants were similar in the three diet groups (Table 1) . Table 2 displays the mean difference between end of study and end of run-in values for 24-h urinary excretion of sodium and potassium. Urinary sodium excretion did not change substantially between end of run-in and end of study on each of the diets, and there was no significant between-diet difference in 24-h urinary sodium excretion (P ¼ 0.15). Compared with the control diet, 24-h urinary potassium excretion increased substantially on both the F/V (Po0.01) and DASH diets (Po0.01). Figure 1 and Table 3 display between-diet differences in PRA. Compared with the control diet, the DASH diet increased mean PRA by 0.37 ng ml À1 h À1 (P ¼ 0.01); the corresponding change in log e PRA was 0.28 (95% confidence intervals (CI) 0.09 to 0.48, P ¼ 0.005) higher for participants on the DASH diet than the control diet. The F/V diet tended to have an intermediate effect between the control and DASH diets. Consistent with the overall trial results, the F/V and DASH diets lowered SBP and diastolic BP compared with the control diet in the 381 participants with complete sets of PRA ( Figure 2 and Table 3 ).
The relationship between Dlog e PRA and DSBP between baseline and end of intervention differed in the three diets (Table 4 and Figure 3 ). In multivariate linear regression (Table 4) , we detected a significant inverse relationship between Dlog e PRA and DSBP in the control diet group (slope ¼ À0.35, P ¼ 0.001). Specifically, in the control-diet group, for each 10 mm Hg reduction in SBP, log e PRA increased by 0.35, which is equivalent to a 41.9% rise in PRA. A significant inverse relationship was not evident in the DASH diet (slope ¼ À0.08, P ¼ 0.32) or F/V diet (slope ¼ À0.002, P ¼ 0.98). Figure 3 displays the fitted linear relationship between Dlog e PRA and DSBP in each diet. In analyses of covariance, the difference in the slopes of Dlog e PRA with DSBP in the DASH and F/V diets compared with the control diet differed significantly (P ¼ 0.04 and P ¼ 0.008, respectively). These analyses indicate that for the same decrease in SBP, the rise in PRA was significantly less in the F/V and DASH diets than in the control diet. The stratified multiple linear regression model fit the data well and explained B28% of the variance in log e PRA (R-squared ¼ 0.28). The residual of the model was normally distributed.
Discussion
The DASH diet has been shown to significantly reduce BP, but the underlying mechanisms are unknown. In this randomized feeding study that enrolled patients with prehypertension and stage 1 hypertension, the DASH dietary pattern lowered BP and also increased PRA compared with a control diet. The F/V diet had intermediate effects. Interestingly, the counter-regulatory response of PRA to SBP change differed in the three diets. On the control diet, reduced SBP was associated with higher PRA, whereas on the F/V and DASH diets, there was no significant relationship between change in SBP and change in PRA. These data suggest that a blunted counter-regulatory response of the reninangiotensin-aldosterone system may contribute to the BP-lowering effect of the F/V and DASH diets.
The relationship between PRA and BP is not consistent, and the response of PRA to anti-hypertensive therapy depends on the mechanism of BP lowering. Both positive and inverse relationships between PRA and BP have been reported. Several studies have shown that although beta-blockers and diuretics both lowered BP, PRA decreased with the beta-blocker and increased with the diuretic. 10, 11 Several studies have examined the effects of micronutrients such as potassium, calcium and magnesium on BP and, to a lesser extent, PRA. The renin-angiotensin-aldosterone system is important in BP regulation. In aggregate, studies indicate that increased potassium intake lowers BP, whereas the effects of magnesium and calcium on BP are uncertain. [12] [13] [14] The effects of these micronutrients on PRA is inconsistent, with some, 
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The effects of dietary patterns on PRA Q Chen et al but not all trials documenting a rise in PRA in response to increased potassium intake. 12,13,15-18 A potassium-induced rise in PRA might result from natriuresis and/possible subsequent volume contraction. Analyses of the DASH-sodium trial revealed that the DASH diet appeared to have a diuretic effect 19 and increased PRA. 20 Increased magnesium intake has not been associated with changes in PRA. 21 High calcium intake has been reported to decrease PRA. 22, 23 The DASH and F/V diets are both relatively high in potassium and magnesium, and the DASH diet is also high in calcium. Hence, although the DASH trial was not designed to identify the nutrients responsible for the effects of the diet on BP and other biomarkers, it is reasonable to speculate that differences in micronutrient intake, for example, higher vs lower levels of potassium, might be responsible for the effects of the diets on PRA levels and on the relationship of change in PRA with change in BP.
An interesting set of findings pertain to the relationship of change in PRA with change in SBP on the control diet. Overall, there was no mean change in SBP compared with baseline after 8 weeks on the control diet; however, as displayed in Figure 2 , there was a wide divergence among individuals, with some individuals experiencing increased SBP on the control diet and others experiencing reduced SBP. Investigators commonly attribute such variability to random measurement The effects of dietary patterns on PRA Q Chen et al error, but our results suggest that such changes are not just measurement error, given that changes in PRA were highly correlated with changes in SBP.
Our study has limitations. First, although we documented a blunted association between change in BP and change in PRA on the F/V and DASH diets, we cannot confirm that this is the mechanism by which these diets lower BP and we cannot determine if the changes in PRA are a sequelae or cause of the change in BP. The DASH trial was not designed to assess which nutrient(s) is(are) responsible for the BP-reducing effect of the DASH diet. In addition, we only have two measurements of PRA, one at the end of run-in and one at the end of the 11-week feeding period. Hence, we cannot determine the time course over the 8 weeks of feeding and whether or not the effects continue beyond 8 weeks. Furthermore, angiotensin II and aldosterone levels were not measured, so any corresponding changes in these levels are unknown. Finally, the sample size is small for subgroup analyses. Among the strengths of our study are the study population that was well balanced in terms of gender and race. In addition the study was a large, controlled feeding study in which all food and beverages were provided.
In summary, the DASH diet increased PRA compared with the control diet. However, for the same magnitude of BP reduction, the rise in PRA was significantly less in both the DASH and F/V diet groups. In aggregate, these results suggest that a blunted counter-regulatory response of the reninangiotensin system is associated with the BP-lowering effect of the F/V and DASH diets.
